Returning for a second year, the upcoming Protein Degradation for CNS Summit will explore the latest developments in degradation research, alongside the leading biopharma companies in the industry.
The industry-leading summit is focused on translating induced proximity, AutoTac, PROTAC and other Targeted Protein Degraders (TPDs) into the clinic to target neurodegeneration and neuro-oncology.
It will take place in Boston, Massachusetts from February 18 to 20.
Raveena Asquith-Bhondi, Conference Producer, Hanson Wade, said: “Attendees will network with peers from discovery, preclinical, translational and clinical backgrounds, all working on developing protein degraders for neurodegeneration and neuro-oncology.
“The latest insights will be explored, with attendees learning from more than 60 industry-leading biopharma and 20-plus expert Biotech and Pharma speakers.”
Agenda highlights include:
- Evaluating the Progress in PK/PD Research for Optimising Drug Efficacy to Enhance the Translation of Therapies for CNS Diseases. Session led by Patrick Wen, Director – Centre for Neuro-Oncology, at the Dana-Farber Cancer Institute.
- Introduction to CNS & BBB Biology to Unlock Deeper Understanding for Aiding Advancements. Workshop led by Marianthi Papakosta, Director of Neuroscience Biology Research, at Neurocrine Biosciences.
- Mechanisms for Extracellular Targeted Protein Degradation in Immune Cells, Neurons & Glia. Session led by Simon Glerup, Chief Scientific Officer, at Draupnir Bio.
The summit organisers are offering Oncology News Today newsletter subscribers 20 per cent off the cost of registering for the event.
To take advantage of the offer register here https://ter.li/9s1qk5 and enter the promo code ONCOLOGYNEWS20.
